|
|
|
|
Дата |
|---|
| 30.12.2025 |
| 29.12.2025 |
| 26.12.2025 |
| 24.12.2025 |
| 23.12.2025 |
| 22.12.2025 |
| 19.12.2025 |
| 18.12.2025 |
| 17.12.2025 |
| 16.12.2025 |
Bid | Ask |
Open |
Min | Max |
Last |
Legal close |
Avg |
Оборот |
Кол-во сделок |
|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
1 651.00
|
|
|
|
|
|
|
|
|
|
|
1 651.00
|
|
|
|
|
|
|
|
|
|
|
1 651.00
|
|
|
|
|
|
|
|
|
|
|
1 651.00
|
|
|
|
|
|
|
|
|
|
|
1 651.00
|
|
|
|
|
|
|
|
|
|
|
1 651.00
|
|
|
|
|
|
|
|
|
|
|
1 651.00
|
|
|
|
|
|
|
|
|
|
|
1 651.00
|
|
|
|
|
|
|
|
|
|
|
1 651.00
|
|
|
|
|
|
|
|
|
|
|
1 651.00
|
|
|
|
|
Olipass Corporation operates nucleic acid biotechnology businesses. The Company mainly develops and produces artificial nuclease therapeutic agents. Olipass also researches gene and protein biotechnologies.
